Download PDF
Semin intervent Radiol 2013; 30(04): 417-424
DOI: 10.1055/s-0033-1359738
Clinical Corner
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Gynecologic Biopsy for Molecular Profiling: A Review for the Interventional Radiologist

Bradley R. Corr
1   Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado
,
Kian Behbakht
1   Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado
,
Monique A. Spillman
1   Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado
› Author Affiliations
Further Information

Publication History

Publication Date:
20 November 2013 (online)

Also available at
    Permissions and Reprints

Abstract

The interventional radiologist is often asked to obtain multiple biopsies of gynecological malignancies for genetic profiling. This article reviews the current indications for gynecological biopsy as well as how the information gained contributes to a personalized medicine plan for the individual patient. The specific focus of this review is the current knowledge and practice of molecular profiling for gynecological malignancies.

Keywords

gynecological cancer - interventional radiology - biopsy - genetic profiling - molecular profiling
 

  • References

  • 1 Howlader NNA, Krapcho M, Garshell J , et al, eds. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013. ; Based on November 2012 SEER data submission, posted to the SEER Web site http://seer.cancer.gov/csr/1975_2010/
    Google Scholar
  • 2 Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351 (24) 2519-2529
    CrossrefPubMedGoogle Scholar
  • 3 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62 (1) 10-29
    CrossrefPubMedGoogle Scholar
  • 4 Parmar MK, Ledermann JA, Colombo N , et al; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361 (9375) 2099-2106
    CrossrefPubMedGoogle Scholar
  • 5 Morgan Jr RJ, Copeland L, Gershenson D , et al; The National Comprehensive Cancer Network. NCCN Ovarian Cancer Practice Guidelines. Oncology (Williston Park) 1996; 10 (11, Suppl): 293-310
    PubMedGoogle Scholar
  • 6 Benedet JL, Bender H, Jones III H, Ngan HY, Pecorelli S ; FIGO Committee on Gynecologic Oncology. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000; 70 (2) 209-262
    CrossrefPubMedGoogle Scholar
  • 7 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20 (5) 1248-1259
    CrossrefPubMedGoogle Scholar
  • 8 Morrow CP, Bundy BN, Kurman RJ , et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991; 40 (1) 55-65
    CrossrefPubMedGoogle Scholar
  • 9 Walboomers JM, Jacobs MV, Manos MM , et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 (1) 12-19
    Google Scholar
  • 10 Scheurer ME, Tortolero-Luna G, Adler-Storthz K. Human papillomavirus infection: biology, epidemiology, and prevention. Int J Gynecol Cancer 2005; 15 (5) 727-746
    CrossrefPubMedGoogle Scholar
  • 11 Delgado G, Bundy BN, Fowler Jr WC , et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol 1989; 35 (3) 314-320
    CrossrefPubMedGoogle Scholar
  • 12 Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 38 (3) 352-357
    CrossrefPubMedGoogle Scholar
  • 13 Koyama T, Mikami Y, Saga T, Tamai K, Togashi K. Secondary ovarian tumors: spectrum of CT and MR features with pathologic correlation. Abdom Imaging 2007; 32 (6) 784-795
    CrossrefPubMedGoogle Scholar
  • 14 Young RH. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. Historical perspective, general principles, mucinous tumors including the Krukenberg tumor. Adv Anat Pathol 2006; 13 (5) 205-227
    CrossrefPubMedGoogle Scholar
  • 15 Young RH. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II. Adv Anat Pathol 2007; 14 (3) 149-177
    CrossrefPubMedGoogle Scholar
  • 16 Bristow RE, del Carmen MG, Pannu HK , et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol 2003; 90 (3) 519-528
    CrossrefPubMedGoogle Scholar
  • 17 Dalla Palma M, Gregianin M, Fiduccia P , et al. PET/CT imaging in gynecologic malignancies: a critical overview of its clinical impact and our retrospective single center analysis. Crit Rev Oncol Hematol 2012; 83 (1) 84-98
    CrossrefPubMedGoogle Scholar
  • 18 Husain A, Akhurst T, Larson S, Alektiar K, Barakat RR, Chi DS. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol 2007; 106 (1) 177-180
    CrossrefPubMedGoogle Scholar
  • 19 Chung HH, Jo H, Kang WJ , et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007; 104 (3) 529-534
    CrossrefPubMedGoogle Scholar
  • 20 Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003; 90 (1) 186-190
    CrossrefPubMedGoogle Scholar
  • 21 Malmström H. Fine-needle aspiration cytology versus core biopsies in the evaluation of recurrent gynecologic malignancies. Gynecol Oncol 1997; 65 (1) 69-73
    CrossrefPubMedGoogle Scholar
  • 22 Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5 (1) 5-23
    CrossrefPubMedGoogle Scholar
  • 23 Tothill RW, Tinker AV, George J , et al; Australian Ovarian Cancer Study Group. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14 (16) 5198-5208
    CrossrefPubMedGoogle Scholar
  • 24 Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol 2010; 118 (1) 88-92
    CrossrefPubMedGoogle Scholar
  • 25 Spentzos D, Levine DA, Ramoni MF , et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22 (23) 4700-4710
    CrossrefPubMedGoogle Scholar
  • 26 Berchuck A, Iversen ES, Lancaster JM , et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005; 11 (10) 3686-3696
    CrossrefPubMedGoogle Scholar
  • 27 Spentzos D, Levine DA, Kolia S , et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005; 23 (31) 7911-7918
    CrossrefPubMedGoogle Scholar
  • 28 Helleman J, Jansen MP, Span PN , et al. Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 2006; 118 (8) 1963-1971
    CrossrefPubMedGoogle Scholar
  • 29 Dressman HK, Berchuck A, Chan G , et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007; 25 (5) 517-525
    CrossrefPubMedGoogle Scholar
  • 30 Ferriss JS, Kim Y, Duska L , et al. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS ONE 2012; 7 (2) e30550
    CrossrefPubMedGoogle Scholar
  • 31 Vella N, Aiello M, Russo AE , et al. 'Genetic profiling' and ovarian cancer therapy (review). Mol Med Rep 2011; 4 (5) 771-777
    PubMedGoogle Scholar
  • 32 Hartmann LC, Lu KH, Linette GP , et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 2005; 11 (6) 2149-2155
    CrossrefPubMedGoogle Scholar
  • 33 Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010; 2010: 162363
    PubMedGoogle Scholar
  • 34 Krakstad C, Birkeland E, Seidel D , et al. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLoS ONE 2012; 7 (12) e52795
    CrossrefPubMedGoogle Scholar
  • 35 Kernochan LE, Garcia RL. Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics. J Natl Compr Canc Netw 2009; 7 (5) 550-556 , quiz 557
    PubMedGoogle Scholar
  • 36 Bourmenskaya O, Shubina E, Trofimov D , et al. Host gene expression profiling of cervical smear is eligible for cancer risk evaluation. J Clin Pathol 2013; 66 (4) 282-285
    CrossrefPubMedGoogle Scholar
  • 37 Hagemann T, Bozanovic T, Hooper S , et al. Molecular profiling of cervical cancer progression. Br J Cancer 2007; 96 (2) 321-328
    CrossrefPubMedGoogle Scholar
  • 38 Havrilesky LJ, Krivak TC, Mucenski JW, Myers ER. Impact of a chemoresponse assay on treatment costs for recurrent ovarian cancer. Am J Obstet Gynecol 2010; 203 (2) e1-e7
    PubMedGoogle Scholar